Articles
12 June 2009
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
https://doi.org/10.4081/hmr.v3i3.573

Idiopathic thrombocytopenic purpura in adults: the treatment paradigm

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
188
Views
564
Downloads

Authors

F Zaja
support@pagepress.org
R Fanin
Idiopathic thrombocytopenic purpura (ITP) in adults is an acquired autoimmune disease characterized by increased platelet destruction, impaired megakaryocytes maturation with reduced platelets production, possible bleeding. The incidence is nearly 50 new cases per million people per year with a female prevalence particularly in younger.1 ITP exhibits a heterogeneous biologic and clinical behavior, frequently has an insidious onset with different severity of thrombocytopenia, chronic course and higher lifetime risk of fatality due to bleeding, mainly intracranial. 2

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Idiopathic thrombocytopenic purpura in adults: the treatment paradigm. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.573